Predictors of Response to Cancer Immunotherapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: 25 October 2024 | Viewed by 82
Special Issue Editors
Interests: immunotherapy; genetics; personalized medicine; cancer epidemiology; molecular epidemiology; translational research
Interests: biostatistics; cancer; epidemiology; healthcare; lung; obesity; personalized medicine; public health; thyroid; translational research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapy has revolutionized cancer treatment and is now the mainstay for advanced non-small-cell lung cancer, melanoma, and other cancers. Yet, while many patients experience dramatic and durable treatment response, others do not benefit from immunotherapy, or they are plagued by extreme, treatment-limiting side effects. Research is ongoing to identify which personal characteristics, biomarkers, and clinical or histological features may explain heterogeneity in immunotherapy effectiveness. Patient’s sex, race, comorbidity, and concurrent medication, as well as histology, specific tumor mutational profile, and tumor immune microenvironment, likely modulate immunotherapy response. For instance, specific gene-expression signatures in immune cells have been demonstrated to predict immunotherapy efficacy. Moreover, research suggests that these factors may behave interactively, either synergistically or antagonistically, to impact immune system response. The availability of reliable predictors of immunotherapy efficacy would have a significant clinical benefit, guiding clinician decision making and improving patient outcomes. Furthermore, profiling-based precision medicine could enable individualized immunotherapy treatment of cancer patients in the future.
This Special Issue is dedicated to understanding predictors, alone or in combination, of immunotherapy efficacy. We warmly welcome submissions, including original papers and reviews, on this critically important topic.
Dr. Stephanie J. Tuminello
Prof. Dr. Emanuela Taioli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- immune checkpoint inhibitors
- cancer
- cancer therapy
- precision medicine
- survival outcomes
